Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
A Stanford research team has patented methods that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
The potency of cancer immunotherapies for solid tumors are often diminished by inadequate metabolic reprogramming and resulting immune evasion in cancer.
Researchers in the Mackall lab at Stanford have developed an adoptive cell therapy modification that enhances anti-tumor activity by disrupting a specific group of genes.
Scientists from the Davis and Mackall labs at Stanford have discovered T cell receptor molecules targeting a novel antigen upregulated in cancer. This discovery has potential value for cancer-targeting therapies, particularly CAR T therapies.
Scientists from the Davis and Mackall labs at Stanford have discovered T cell receptor molecules targeting a novel antigen upregulated in cancer. This discovery has potential value for cancer-targeting therapies, particularly CAR T therapies.
Researchers at Stanford have developed chimeric antigen receptors (CARs) that target glypican-2 (GPC2) and can be used to treat solid tumors. CAR-engineered T cells have shown great promise as cancer therapeutics.
Researchers at Stanford have developed a method to direct T cell fate toward the T stem cell memory (TSCM) phenotype during ex vivo expansion for adoptive cell transfer (ACT) therapies.